Found: 73
Select item for more details and to access through your institution.
COVID‐19: Histopathological correlates of imaging patterns on chest computed tomography.
- Published in:
- Respirology, 2021, v. 26, n. 9, p. 869, doi. 10.1111/resp.14101
- By:
- Publication type:
- Article
Effects of erlotinib therapy on [C]erlotinib uptake in EGFR mutated, advanced NSCLC.
- Published in:
- EJNMMI Research, 2016, v. 6, n. 1, p. 1, doi. 10.1186/s13550-016-0169-8
- By:
- Publication type:
- Article
KRAS Mutated Non-Small Cell Lung Cancer: A Distinct Disease Entity?
- Published in:
- Current Medical Literature: Lung Cancer, 2013, v. 6, n. 3, p. 63
- By:
- Publication type:
- Article
Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
- Published in:
- Cellular Oncology (2211-3428), 2014, v. 37, n. 5, p. 353, doi. 10.1007/s13402-014-0196-2
- By:
- Publication type:
- Article
Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Expert opinion on NSCLC small specimen biomarker testing - Part 1: Tissue collection and management.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Correction to: Diagnosis of atypical carcinoid can be made on biopsies > 4 mm<sup>2</sup> and is accurate.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Diagnosis of atypical carcinoid can be made on biopsies > 4 mm<sup>2</sup> and is accurate.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2022, v. 480, n. 3, p. 587, doi. 10.1007/s00428-022-03279-7
- By:
- Publication type:
- Article
Influence of preanalytical variables on performance of delta-like protein 3 (DLL3) predictive immunohistochemistry.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2021, v. 478, n. 2, p. 293, doi. 10.1007/s00428-020-02848-y
- By:
- Publication type:
- Article
Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Testing for ROS1 in non-small cell lung cancer: a review with recommendations.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Prognostic and predictive biomarkers in lung cancer. A review.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2014, v. 464, n. 3, p. 347, doi. 10.1007/s00428-014-1535-4
- By:
- Publication type:
- Article
Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2013, v. 462, n. 5, p. 547, doi. 10.1007/s00428-013-1404-6
- By:
- Publication type:
- Article
Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2012, v. 461, n. 6, p. 629, doi. 10.1007/s00428-012-1324-x
- By:
- Publication type:
- Article
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.
- Published in:
- 2012
- By:
- Publication type:
- journal article
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2012, v. 461, n. 3, p. 245, doi. 10.1007/s00428-012-1281-4
- By:
- Publication type:
- Article
Biopsy appearances easily mistaken for malignancy in gastrointestinal endoscopy.
- Published in:
- Histopathology, 1983, v. 7, n. 1, p. 141, doi. 10.1111/j.1365-2559.1983.tb02227.x
- By:
- Publication type:
- Article
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262473
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262473
- By:
- Publication type:
- Article
First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-small- cell lung cancer . .
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262473
- By:
- Publication type:
- Article
First-in-human study of<sup> 89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262473
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
Quantification of PD-L1 expression with [<sup>18</sup>F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD-L1 expression with [18F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD‐L1 expression with [ <sup>18</sup>F]BMS‐986192 PET/CT in patients with advanced stage non‐small‐cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD‐L1 expression with [<sup>18</sup>F]BMS‐986192 PET/CT in patients with advanced stage non‐small‐cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD‐L1 expression with [<sup>18</sup>F]BMS‐986192 PET/CT in patients with advanced stage non‐small‐cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 8, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD-L1 expression with [<sup>18</sup>F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD‐L1 expression with [ 18F]BMS‐986192 PET/CT in patients with advanced stage non‐small‐cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD-L1 expression with [18F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD-L1 expression with [<sup>18</sup>F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 4, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD‐L1 expression with [<sup>18</sup>F]BMS‐986192 PET/CT in patients with advanced stage non‐small‐cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 3, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?
- Published in:
- Familial Cancer, 2016, v. 15, n. 2, p. 297, doi. 10.1007/s10689-015-9853-5
- By:
- Publication type:
- Article
A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation.
- Published in:
- Familial Cancer, 2013, v. 12, n. 3, p. 373, doi. 10.1007/s10689-012-9593-8
- By:
- Publication type:
- Article
External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different.
- Published in:
- Journal of Pathology: Clinical Research, 2020, v. 6, n. 2, p. 138, doi. 10.1002/cjp2.153
- By:
- Publication type:
- Article
Tumor size does not predict pathological complete response rates after pre-operative chemoradiotherapy for non-small cell lung cancer.
- Published in:
- Acta Oncologica, 2013, v. 52, n. 3, p. 676, doi. 10.3109/0284186X.2012.718794
- By:
- Publication type:
- Article
The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization.
- Published in:
- PLoS ONE, 2014, v. 9, n. 11, p. 1, doi. 10.1371/journal.pone.0112159
- By:
- Publication type:
- Article
Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3′-Deoxy-3′-[<sup>18</sup>F]fluorothymidine Positron Emission Tomography
- Published in:
- PLoS ONE, 2013, v. 8, n. 5, p. 1, doi. 10.1371/journal.pone.0063705
- By:
- Publication type:
- Article
Loose Tumor Cells in Pulmonary Arteries of Lung Adenocarcinoma Resection Specimens: No Correlation With Survival, Despite High Prevalence.
- Published in:
- Archives of Pathology & Laboratory Medicine, 2024, v. 148, n. 5, p. 588, doi. 10.5858/arpa.2023-0009-OA
- By:
- Publication type:
- Article
Predictive Markers Require Thorough Analytic Validation.
- Published in:
- Archives of Pathology & Laboratory Medicine, 2019, v. 143, n. 8, p. 907, doi. 10.5858/arpa.2019-0112-LE
- By:
- Publication type:
- Article
How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non--Small Cell Lung Cancer.
- Published in:
- 2019
- By:
- Publication type:
- Editorial
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
- Published in:
- Archives of Pathology & Laboratory Medicine, 2018, v. 142, n. 3, p. 321, doi. 10.5858/arpa.2017-0388-CP
- By:
- Publication type:
- Article